Merus is a clinical-stage oncology company developing antibody therapeutics. Using its Biclonics® platform, Co. has produced and is developing the following candidates: MCLA-128 (zenocutuzumab) for the treatment of solid tumors that harbor Neuregulin 1 gene fusions; MCLA-117 for the treatment of acute myeloid leukemia; MCLA-158 for the treatment of solid tumors; and MCLA-145, developed in collaboration with Incyte Corporation, for the potential treatment of solid tumors and a hematological malignancy, B-cell lymphoma. Co. is also developing a late-stage pre-clinical candidate, MCLA-129 in collaboration with Betta Pharmaceuticals Co. Ltd., for the potential treatment of solid tumors. The MRUS average annual return since 2016 is shown above.
The Average Annual Return on the MRUS average annual return since 2016 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether MRUS average annual return since 2016 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MRUS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free MRUS Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
